The late region of the human neurotropic JC virus encodes a 71 amino acid protein, named Agnoprotein, whose biological function remains elusive. Here we demonstrate that in the absence of other viral proteins, expression of Agnoprotein can inhibit cell growth by deregulating cell progression through the cell cycle stages. Cells with constitutive expression of Agnoprotein were largely accumulated at the G2/M stage and that decline in the activity of cyclins A and B is observed in these cells. Agnoprotein showed the ability to augment p21 promoter activity in transient transfection assay and a noticeable increase in the level of p21 is detected in cells continuously expressing Agnoprotein. Results from binding studies revealed the interaction of Agnoprotein with p53 through the N-terminal of the Agnoprotein spanning residues 1 -36. Co-expression of p53 and Agnoprotein further stimulated transcription of the p21 promoter. Thus, the interaction of p53 and Agnoprotein can lead to a higher level of p21 expression and suppression of cell cycle progression during the cell cycle.
Introduction
The human neurotropic polyomavirus, JCV, is an established etiologic agent of the fatal demyelinating disease in humans, Progressive Multifocal Leukoencephalopathy (PML) (for review see Berger et al., 1998) . In addition, recent studies from several groups point to the association of this virus with several human cancers including tumors of neural origin (Caldarelli-Stefano et al., 2000; Del Valle et al., 2000 , 2001a Gallia et al., 1998; Khalili et al., 1999; Rencic et al., 1996) . The genome of JCV is comprised of a double-stranded circular DNA that contains three functional regions including the viral early and late coding genes, and the non-coding regulatory sequence (Frisque et al., 1984) . The viral early genome, expressed prior to DNA replication is responsible for production of the viral regulatory proteins, small and large T-antigen, while the expression of the late genome results in the accumulation of the capsid proteins, VP1, VP2, and VP3. In addition, the leader of the late transcripts encompasses an open reading from encoding a 71 amino acid protein named Agnoprotein (Okada et al., 2001) . While earlier investigations on the polyomaviruses have led to the identification of several biological activities of the viral early protein, functional importance of Agnoprotein on the control of viral gene expression and its effect on host remains largely unknown. Earlier studies on SV40 suggested that Agnoprotein may contribute at various stages of the viral lytic cycle, including transcription of the viral genome, translation of viral late proteins, processing of viral late proteins, assembly of virions, and nuclear translocation of the major capsid proteins, VP1 (Alwine, 1982; Carswell and Alwine, 1986, Hay and Aloni, 1985; Hay et al., 1982; Ishii et al., 1996; Khalili et al., 1988; Resnick and Shenk, 1986; Stacy et al., 1989) . Results from subcellular localization studies revealed that similar to its counterpart in SV40 (Nomura et al., 1983; Rinaldo et al., 1998) , JCV Agnoprotein is accumulated in the cytoplasmic and nuclear membrane of the cells with a minor appearance in the nuclei (Okada et al., 2001 ). More recently, it was demonstrated that JCV Agnoprotein has the ability to physically interact with T-antigen. The association of Agnoprotein and T-antigen may impact upon the activity of T-antigen on the control of viral gene transcription and replication (Safak et al., 2001) . As the T-antigen of JCV, through the interaction with cellular proteins which are responsible for several regulatory pathways, exerts its transforming activity in vitro and tumorigenicity in vivo (Gordon et al., 2000; Krynska et al., 1997 Krynska et al., , 1999 , one may envision a role for Agnoprotein, either alone or together with T-antigen in modulation of several cellular events. Here we demonstrate that JCV Agnoprotein, by de-regulating cell cycle progression, inhibits cell growth and proliferation. This event, which occurs in the absence of T-antigen, seems to be mediated through the enhancement of tumor suppressor protein such as p21 by Agnoprotein and the interaction of this protein with p53.
Results
We created stable NIH3T3 cell lines that constitutively express Agnoprotein by using a plasmid containing the Agnogene in fusion with the mutant variant of GFP, yellow fluorescent protein (YFP). Examination of protein extracts from these cells showed expression of the YFP-Agnoprotein fusion protein which was appropriately localized in the cytoplasmic perinuclear membrane of the cells. Figure 1a illustrates results from Western blot and Figure 1b fluorescence microscopy analyses of one of the Agnoprotein-producing cells. The control cells expressing YFP showed no evidence for Agnoprotein production by Western blot or cellular compartmentalization of YFP. Other cell types such as the human astrocytic cell line, U-87MG, transduced with retrovirus containing Agnogene, which showed a high level of Agnoprotein production upon transduction with Agnoprotein-retroviral constructs, also exhibited accumulation of this protein around the nuclei (data not shown). Examination of the growth rate of cells expressing either YFP-Agnoprotein or YFP alone revealed an approximately 50% decrease in the number of Agnoprotein producing cells compared to that seen in the control cells ( Figure  1c) . Results from FACS analysis of Agnoprotein producing cells revealed an abnormal progression of these cells through the cell cycle phases. At 0 h post serum induction, greater than 90% of the control cells expressing YFP were found at the G0/G1 phase ( Figure 2a) . As time progressed, the cells began to pass the S phase and accumulated at G2/M. By 21 h post-serum induction, only 39.7% of the cells were found at the G1 and greater than 49.3% of the cells were found at G2/M. After 25 h, again, cells appeared to depart from G2/M and accumulate at the G1 phase. At 29 h, nearly 61% of cells were found at the G1 and only 23% were detected at G2/M.
As shown in Figure 2b , the Agnoprotein producing cells exhibited a different pattern of the cell cycle than the control cells. In general, it is evident that Agnoprotein slows the progression of cells through the cell cycle. Immediately following serum stimulation (time 0), compared to the control, more cells (39.2%) were detected at the G2/M. Also, at the same time point, 56.5% of the Agnoprotein producing cells were found at the G1 stage. Interestingly, at 16 h and 21 h after serum induction the number of cells began to decline at the G1 stage and elevate at the S phase, a substantial number of cells were detected at the G2/M phase. At the later times after serum induction, i.e. 25 and 29 h, the number of cells at G2/M remained at high levels. These data indicate that expression of Agnoprotein de-regulates cell cycle progression at various stages, most noticeably by retaining cells at the G2/M stage.
To gain insight into the mechanism whereby Agnoprotein affects the cell cycle progression, we examined the level of expression and activities of several proteins which are involved in the control of the cell cycle. The initial examination of cyclin D, cdk4, cdk6, cyclin E and cdk2 in the Agnoprotein producing cells revealed no detectable changes in the levels and activities of these proteins in comparison to those observed in the control cells (data not shown). Since cyclin A/cdc2 and cyclin B/cdc2 provide a regulatory role during the S and G2/M stages, we focused our attention on evaluating the levels and activities of these proteins. Examination of cyclin A production at various times after serum induction showed a comparable level of this protein in the control and Agnoprotein producing cells ( Figure 3 , compare a to b). The level of housekeeping protein such as Grb-2 was determined and used as a control for equal protein loading in gel analysis ( Figure 3a) . Evaluation of the activity of the cyclin A by H1 kinase assay reproducibly showed a 35 and 55% decrease in the kinase activity of cyclin A from Agnoprotein producing cell at 16 and 21 h after serum induction, respectively ( Figure 3d ). Noticeably, the kinase activity of the cyclin A complex in the control cells, but not the Agnoprotein producing cells, was declined at 29 h post-serum induction. Examination of cyclin B levels by Western blot analysis revealed an increase in the level of cyclin B after 21 h serum stimulation in both Agnoprotein producing and control cells. ) were stimulated by media containing 10% fetal calf serum. Total protein extract (50 mg) from cells harvested at the indicated time points after stimulation was analysed by Western blot using anti-cyclin A antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The bottom panels illustrate results from Western blot using anti-Grb2 antibody serving as a control for protein loading in gels. Associated kinase activity of cyclin A from YFP and YFP-Agnoprotein producing NIH 3T3 cells (c) was assessed by H1 kinase assay. Approximately 220 mg of protein extract from each cell at various time points after serum induction were prepared and immunoprecipitated with anti-cyclin A antibody as described previously (Kim et al., 1994) . Phosphorylated histone H1 was identified following SDS -PAGE and autoradiography. The kinase activity is quantitated by measuring [
32 P] incorporation in H1 in each sample by scintillation counting and is expressed as counts/min on the y axis and time in hours on the x axis. Kinase assay was repeated two times giving an interassay standard deviation within 10% after normalization for protein amount Figure 4 Expression of cyclin B and its associated kinase activity in the control and Agnoprotein producing cells. Western blot analysis of protein extracts from NIH3T3 YFP (a) and NIH3T3 YFP-Agnoprotein (b) at various times after serum starvation using anti-cyclin B antibody. The levels of Grb2, housekeeping gene, served as a control for protein loading in this experiment. Kinase activity of cyclin A immunocomplex from YFP and YFP-Agnoprotein producing NIH3T3 cells (c). Kinase activity was determined by H1 kinase assay and the average of two experiments after normalization for protein levels is shown Since the activity of cyclins can be controlled by various inhibitory proteins, in the next series of experiments, we examined the level of several inhibitors of the cell cycle including p27 and p21. Results from Western blot analysis revealed no significant differences in the levels of p27 in the control cells and cells expressing Agnoprotein (Figure 5a ). However, it was evident that the level of p21 is increased in cells expressing Agnoprotein (Figure 5b) . The level of expression of other cellular proteins including actin, remained unchanged in the presence and absence of Agnoprotein (Figure 5c ). Examination of p21 levels at various time points after serum induction revealed a subtle increase in the level of this protein during all stages particularly at the later times that correlates with S and G2/M stages (data not shown). Enhancement of p21 in cells with slow growth rates and suppression of cell cycle progression, particularly at the G2/M stage, is in accord with recent reports ascribing a role for p21 at the G2/M transition (Niculescu et al., 1998) . To further investigate the effect of Agnoprotein upon p21 expression, we examined the ability of Agnoprotein to enhance transcriptional activity of the p21 promoter. As shown in Figure 5d , transcriptional activity of the p21 promoter was increased upon expression of Agnoprotein in transfected cells. The experiment was performed in Saos-2 cells, which lacks endogenous p53, a known activator of the p21 promoter. As expected, ectopic expression of p53 elevated p21 promoter activity in these cells. Of interest, co-production of p53 and Agnoprotein caused a synergistic elevation of the p21 promoter. These observations suggest that Agnoprotein modestly increases the level of p21 promoter transcription, and its cooperation with p53 further elevates expression of p21 in the cells.
Examination of p53 levels by Western blot showed no significant differences in the level of p53 expression in the control and the Agnoprotein producing cells (Figure 6a) . To investigate the possible physical interaction of Agnoprotein with p53, first we used GST pull-down assay in which in vitro synthesized 35 Slabeled p53 was incubated with GST alone or GSTAgnoprotein fusion protein. After 1 h incubation at 48C, the complexes bound to resin were pulled down and washed with binding buffer as described previously (Safak et al., 2001) . Bound proteins were diluted by boiling in Laemmli buffer, and after analysis by SDS -PAGE, were detected by autoradiography. As shown in Figure 6b , the 53 kDa 35 S-labeled p53 was retained by the GST-Agnoprotein, but not by GST alone. In lane 1, one-tenth of the in vitro synthesized p53 which was used in GST assay was directly analysed by SDS -PAGE, followed by autoradiography. In the reciprocal experiment, in vitro synthesized Agnoprotein was incubated with GST or GST-p53 and the bound proteins were analysed by SDS -PAGE followed by autoradiography. As shown in Figure 6c , a band corresponding to Agnoprotein was detected in GSTp53, but not GST. In the next series of experiments we performed co-immunoprecipitation/Western blot analysis of protein extracts from the control and Agnoprotein producing cells using anti-p53 antibody to immunoprecipitate the p53 complex, then examined for the presence of Agnoprotein in the immunocomplex by using anti-Agnoprotein in Western blot assay. As shown in Figure 6d , a distinct band corresponding to Agnoprotein was observed by analysing the immunocomplex from the Agnoprotein cells, suggesting the association of p53 and Agnoprotein in the cell extract.
In the third approach to demonstrate the interaction of Agnoprotein and p53, protein extracts from YFP-Agnoprotein-producing NIH3T3 and the control NIH3T3 cells expressing only YFP were mixed with GST-p53 or GST and the bound proteins were analysed by Western blot using anti-Agnoprotein antibody. As shown in Figure 6e , a band corresponding to YFP-Agnoprotein was observed in GST-p53, but not on GST fractions. To gain more insight into the Agnoprotein interaction with p53, we employed GST pull-down assay using various mutants of Agnoprotein to determine the region within Agnoprotein that associates with p53. As shown in Figure 6f , results from the binding study demonstrate that the region of Agnoprotein spanning the N-terminal of the protein between residues 1 -36 is sufficient for binding to p53. This region of Agnoprotein encompasses a helix -loop -helix structure which has 63% homology with the SV40 Agnoprotein (data not shown). All of these results provide strong evidence for the ability of Agnoprotein to interact with p53 to regulate expression of the downstream targets for p53, such as p21, which are involved in the control of cell cycle progression.
Discussion
In this study we demonstrate that unlike its early protein, T-antigen, which promotes cell growth, expression of the JCV late leader protein, Agnoprotein, results in suppression of cell proliferation. The results presented in this communication provide evidence that Agnoprotein affects cell cycle progression most probably by stalling cells at the G2/M stage. Furthermore, our results show that the activity of cyclin A and particularly cyclin B is decreased in cells expressing Agnoprotein. Examination of various tumor suppressors revealed that cells with a continuous expression of Agnoprotein have a higher level of p21, and that Agnoprotein has the ability to stimulate the activity of the p21 promoter. While the mechanism whereby Agnoprotein enhances p21 expression remains to be investigated, our preliminary observation indicates that in Agnoprotein producing cells, where a higher level of Immunoprecipitation was performed using a specific antibody that detects p53 (pAb 421). Immunoprecipitated proteins were resolved by SDS -PAGE and analysed by Western blot using anti-Agnoprotein antibody. The position of the fusion Agnoprotein is shown by an arrow. The asterisk points to a non-specific band seen in both extracts. (e) Approximately 250 mg of protein extracts from control cells expressing YFP or cells expressing GFP-Agnoprotein were analysed by GST pull-down assay using GST or GST-p53 as indicated above the lanes. Lanes 1 and 2 represent analysis of 50 mg of proteins from each cell which were used in the binding experiment. The arrow points to the position of YFP-Agnoprotein as detected by Western blot. (f) In vitro 35 S-methionine-labeled p53 protein was analysed by GST pull-down using various regions of the Agnoprotein (as indicated) fused to GST as described in (b). The position of p53 is shown by an arrow p21 is determined, the pRb tumor suppressor is less phosphorylated (Darbinyan, unpublished observations) . This observation suggests a role for p21 and pRb in the control of the G2/M phase in cells expressing Agnoprotein. The importance of this event in replication of JCV in the infected cells remains to be investigated. However, based on the opposing effect of T-antigen and Agnoprotein upon cell proliferation, one may envision a model in which at the early stage, Tantigen by promoting various steps which are involved in gene expression and DNA replication triggers the initial events which are important for the viral lytic cycle. At the late stages of the viral infection cycle, Agnoprotein by stalling cells at G2/M and deregulating the other phases of the cell cycle may ensure successful viral gene expression, replication, and assembly in the cells.
Recently, JCV has been linked to various tumors of central nervous system origin, including medulloblastoma, glioblastoma, and others (Del Valle et al., 2001a; Khalili et al., 1999) . Examination of T-antigen expression in tumor tissue revealed that not all tumor cells express T-antigen. More recent evaluation of these tumors for the other viral proteins showed a substantial level of Agnoprotein in large numbers of tumors which contain the JCV genome (Del Valle et al., 2001c) . While the significance of Agnogene expression in development of brain tumors and growth of tumor cells remains to be investigated, one may postulate that cross-communication of JCV T-antigen and Agnoprotein with each other (Safak et al., 2001) and the other cellular proteins, including p53, impacts upon the growth rate of these tumor cells. In fact, our results from protein -protein interaction studies revealed that similar to T-antigen, Agnoprotein can also interact with p53. This interaction, however, may not stabilize, and thus, elevate the level of p53 in the cells. However, it is possible that this event may influence the transregulatory function of p53 upon a number of regulatory pathways which are involved in cell cycle control. The observed activation of p21 gene expression in NIH3T3 cells expressing Agnoprotein may be mediated, perhaps partly, through cooperation with p53. Although one may also consider a p53-independent mechanism for p21 activation by Agnoprotein as evidenced by our results from the p53 null cell line. Thus, it is likely that expression of Agnoprotein in cells affects several regulatory events that are involved in the control of the cell cycle.
Materials and methods
Cell culture, transfection, and plasmids NIH3T3 and Saos-2 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Transfections were performed on approximately 5 -7610 5 cells per 60 mm dish using the calcium phosphate precipitation method (Graham and van der Eb, 1973) . After 48 h, cells were harvested for protein extract preparation or were transferred to 100 mm plates containing DMEM plus 10% FBS and Geneticin at a concentration of 0.5 mg/ml for the selection of stably transfected cells.
Plasmids that were used in the various transfections were as follows: pCMV-Agnoprotein and pGEX-1lT-Agnoprotein, both of which have been described previously (Safak et al., 2001) . pYFP-Agnoprotein was created by PCR amplification of the gene from the plasmid pBJC containing the Mad-1 strain of JCV using the following primers containing a BamHI and EcoRI site, respectively: 5'-ACGTCCAGGATC-CATGGTTCTTCGCCAGCTGTCA-3' and 5'-ACGTCCA-GAATTCCTATGTAGCTTTTGGTTCAGG-3'. After gel purification, the amplicon was digested with BamHI and EcoRI and the Agnogene was subcloned into the same sites of the pEYFP-N1 vector multiple cloning site (Clontech). All constructs were verified by sequencing. p21-Luciferase was obtained from Dr B Sawaya (Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA).
Protein extract preparation Western blot analysis, and H1 kinase assay
For protein extraction, cells were lysed for 20 min on ice in lysis buffer (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.5% NP40) containing 10 mg/ml leupeptin, 2 mg/ml aprotinin, 100 mg/ml PMSF, 100 mg/ml TPCK; and 10 mg/ml pepstatin. Cell debris was removed by centrifugation and the supernatant was collected for protein concentration by Bradford analysis (Bio-Rad, Hercules, CA, USA). Approximately 50 mg of the proteins were separated by SDS -PAGE and analysed by Western blot using specific antibodies as detailed in the figure legends. Briefly, proteins were transferred to Optitran supported nitrocellulose (Schleicher & Schuell) and blocked in PBS-Tween 20 (0.1%) containing 10% non-fat dry milk for 45 min. Blots were then incubated in primary antibody for 2 h, washed 3610 min in PBS-T, incubated in anti-mouse or anti-rabbit secondary antibody conjugated to horseradish peroxidase for an additional hour, followed by washing 3610 min in PBS-T. Blots were developed with ECL-Plus (Amersham Pharmacia, Piscataway, NJ, USA) and detected by autoradiography.
For immunoprecipitation, 150 -250 mg of protein lysates were incubated while rotating overnight at 48C with anti-p53 antibody. Protein complexes were pulled down by incubating with 30 ml of pre-washed protein A Sepharose for 2 h at 48C. The Sepharose A/protein complexes were then washed twice in lysis buffer, resuspended in 10 ml of 66 SDS loading buffer, and incubated for 5 min at room temperature. Samples were centrifuged, the supernatant was boiled at 958C for 10 min and separated by SDS -PAGE followed by Western blot analysis using anti-Agnoprotein antibody.
For H1 kinase assay, approximately 200 mg of the same protein extract that was examined by Western blot were immunoprecipitated with antibodies as specified in each experiment. Approximately 30 ml of packed protein-A sepharose beads in lysis buffer were added and incubated at 48C for 3 h. The immunoprecipitates were assayed for kinase activity for 30 min at 308C in buffer containing 5 mCi of [g 32 P]ATP, 5 mg of histone H1, 1 mM DTT, 10 mM MgCl 2 , and 20 mM Tris (pH 7.4). The reaction was stopped by the addition of SDS sample buffer and analysed by SDS -PAGE followed by autoradiography. Antibodies used in these studies included: rabbit anti-Agno protein (Del Valle et al., 2001c) ; rabbit anti-cyclin A (C-19), mouse anti-cyclin B1 (clone GNS1), mouse anti-p53 (Ab-1) and rabbit anti-p21/ WAF-1 (Ab-5) from Oncogene Science. The integrity of all protein extract preparations and protein loading on to the gels was assessed by examination of the level of housekeeping proteins such as Grb-2 and actin.
Cell proliferation and flow cytometry
Cells were plated in 35 mm petri dishes at a density of 1610 4 cells/plate and maintained in DMEM plus 10% FBS. Cells were collected at various times and cell proliferation was assessed by determining total cell number by phase contrast microscopy.
For flow cytometry, cells were synchronized by serum starvation for 72 h. At various times after serum stimulation (as indicated in the figure legends), cells were collected by centrifugation and were resuspended in 300 ml of PBS containing 10 mg/ml of propidium iodide and 250 mg/ml or RNase A. Samples were incubated at 378C for 30 min and kept at 48C until flow cytometry was performed with Becton Dickinson FACScan flow cytometer.
GST pull-down assay
For in vitro binding assay, either 3 ml of 35 S-labeled in vitro translated p53 or Agnoprotein were incubated with 5 mg of GST or fusion proteins. GST-Agnoprotein or GST-p53, coupled to glutathione sepharose beads in 300 ml of LB150 (50 mM Tris-HCl, pH 7.4; 150 mM NaCl, 5 mM EDTA, 0.1% NP40) for 1 h at 48C with continuous rocking. After incubation, the beads were precipitated and washed five times with LB150 buffer. The bound proteins were eluted with Laemmli sample buffer, heated at 958C for 10 min, and were separated by SDS -PAGE. p53 or Agnoprotein was detected by autoradiography.
